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Harmonin-homology domainCerebral cavernous malformations (CCM) are neurovascular dysplasias affecting up to 0.5% of the
population. Mutations in the CCM2 gene are associated with acquisition of CCM. We identify a pre-
viously uncharacterized domain at the C-terminus of CCM2 and determine its 1.9 Å resolution crys-
tal structure. Because this domain is structurally homologous to the N-terminal domain of
harmonin, we name it the CCM2 harmonin-homology domain or HHD. CCM2 HHD is observed in
two conformations, and we employ analytical ultracentrifugation to test its oligomerization. Addi-
tionally, CCM2 HHD contains an unusually long 13-residue 310 helix. This study provides the ﬁrst
structural characterization of CCM2.
Structured summary of protein interactions:
CCM2 binds to CCM3 by pull down (View interaction)
CCM2 and CCM2 bind by X-ray crystallography (View interaction)
CCM2 and CCM2 bind by molecular sieving (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction KRIT1 via conserved NPxY/F motifs in the KRIT1 N-terminus [8].Cerebral cavernous malformations (CCM) are neurovascular
dysplasias that occur in up to 0.5% of the population [1]. Both the
familial and sporadic forms of the disease most commonly result
in the formation of hemorrhage-prone lesions in the brain [1] that
are associated with stroke, seizure, or other neurological sequelae
[1]. Approximately 20% of familial cases of CCM are associated with
autosomal dominant inheritance of mutations in the gene CCM2
(malcavernin; osmosensing scaffold for MEKK3, OSM) [1]. The forma-
tion of lesions is thought to be associated with a ‘second-hit’ so-
matic mutation resulting in complete loss of functional CCM2
[2,3]. CCM2 is also essential for embryonic angiogenesis, and its
endothelial-speciﬁc loss is lethal mid-gestation [4,5]. The molecu-
lar and structural underpinnings of CCM2 function are therefore of
signiﬁcant cell biological and clinical interest.
CCM2 is a 444 amino acid protein predicted to contain a phos-
photyrosine binding (PTB) domain at its N-terminus [6]. It is
thought to interact directly with both KRIT1 (Krev interaction
trapped-1; CCM1) and CCM3 (programmed cell death 10; PDCD10)
to form the CCM complex [7]. The CCM2 PTB domain interacts withCCM2 also directly interacts with CCM3, but the interaction inter-
face is not well characterized [7,9]. CCM2 is therefore the hub of
the CCM complex, scaffolding to both KRIT1 and CCM3. CCM2 has
also been implicated as an osmosensitive scaffold for p38 MAP ki-
nase cascades [10,11] and in degradation of the GTPase RhoA [5,12].
The C-terminal portion of CCM2 has not been well described.
This approximately 200 amino acid region cannot be homology
modeled to known protein domains [13]. It is not yet known
whether the CCM2 C-terminus contains a folded domain, nor
how that domain may function in the cell. The C-terminus does,
however, appear to be capable of inducing cell death through a
pathway involving the neurotrophin receptor TrkA [13]. The
molecular basis for this requirement is not understood.
In this study, we provide the ﬁrst molecular level analysis and
crystal structure of the C-terminus of CCM2. We ﬁnd a helical do-
main that bears distinct structural similarity to the N-terminal do-
main of the Usher syndrome scaffolding protein harmonin [14,15]
that we ﬁnd can exist in two distinct conformational states.
2. Materials and methods
2.1. Protein expression and puriﬁcation
Four human CCM2 (UniProt ID: Q9BSQ5) constructs were sub-
cloned into a modiﬁed pET32 vector with a TEV-cleavable N-termi-
Fig. 1. Domain organization of CCM2. (A) Domain schematic of CCM2. The
predicted PTB domain is shown in purple and the C-terminal regions identiﬁed in
this study are indicated; (B) limited proteolysis of full-length CCM2 (CCM2-FL)
using a serial dilution of proteases reveals a proteolytically resistant portion of
CCM2 (CCM2-CT); (C) limited proteolysis using CCM2-CT as input identiﬁes a
second proteolytically resistant region (CCM2-CT2); (D) pull-down assay. CCM2-FL
or CCM2-HHD were bound to nickel-beads and incubated with CCM3. Right hand
lane is CCM3 pull-down by empty beads.
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(residues 231–438), CCM2-CT3 (residues 283–438) and CCM2-
HHD (residues 283–379). These were expressed in Escherichia coli
Rosetta (DE3) cells (Novagen) and puriﬁed (Supplementary data).
2.2. Limited proteolysis
Limited proteolysis was performed on CCM2-FL and CCM2-CT
as described in Supplementary data.
2.3. Crystallization and structure solution of CCM2 C-terminal domain
Optimized CCM2-HHD crystals were obtained with precipitant
conditions of 2.072 M ammonium sulfate and 0.2 M potassium for-
mate (Supplementary data). Because CCM2-HHD has no discern-
able homology to other determined protein structures by
sequence alignment, we determined the structure by the single-
wavelength anomalous diffraction (SAD) method using an osmium
derivative (Supplementary data). The structure is deposited in the
PDB with accession code 4FQN.
2.4. Light scattering and analytical ultracentrifugation
SEC-MALS was performed on puriﬁed CCM2-HHD or CCM2-
HHD-E290R concentrated to 1 mg/ml. Data analysis was per-
formed using ASTRA 6 software (Wyatt Technology). Sedimenta-
tion velocity experiments were performed to monitor possible
mass action in the oligomerization behavior of CCM2. Both wild-
type and CCM2-HHD-E290R were measured over 13–224 lM for
the wild-type and 11–239 lM for CCM2-HHD-E290R (Supplemen-
tary data).
3. Results
3.1. CCM2 contains a C-terminal domain
The CCM2 protein contains an N-terminal ﬂexible loop of
approximately 60 residues, a predicted PTB domain (encoded
approximately by residues 60–220) [6], and a C-terminal region
(residues 220–444) (Fig. 1A). No sequence homology to struc-
tural domains has previously been detected in the C-terminal re-
gion of CCM2, although it has been suggested to play a role in
promoting apoptotic signaling by the TrkA receptor tyrosine ki-
nase [13] and has predicted secondary structure. To identify
whether a folded domain exists at the CCM2 C-terminus, we con-
ducted limited proteolysis on full-length CCM2 (CCM2-FL) by incu-
bating it with serial dilutions of three different proteases. A species
of approximately 21 kDa molecular mass was present after treat-
ment with all three proteases (Fig. 1B) that N-terminal sequencing
identiﬁed to begin at A232. This is slightly downstream from the
predicted PTB domain, indicating the presence of a proteolytically
stable C-terminal region of CCM2. Therefore, we produced a CCM2
construct encompassing residues R231–S438 (CCM2-CT) that we
found by circular dichroism analysis to contain approximately
40% helical and 10% strand content, suggesting that the C-terminus
of CCM2 can independently fold as a stable domain. Because this
region of the protein was recalcitrant to crystallization, however,
we conducted a second limited proteolysis analysis (Fig. 1C). This
yielded another region (CCM2-CT2) of approximately 17 kDa
molecular mass that N-terminal sequencing determined to start
at C269. Taking into account the limited proteolysis results and
secondary structure predictions, we designed two further CCM2
constructs encompassing residues S283–S438 (CCM2-CT3) and
residues S283–G379 (CCM2-HHD). This analysis provides direct
experimental evidence in support of a folded domain at the C-ter-
minus of CCM2 (Fig. 1A).3.2. The CCM2 C-terminal domain does not interact with CCM3
CCM2 has been shown to interact with another cerebral cav-
ernous malformation-associated protein, CCM3 [7,9], through a
small region C-terminal to the predicted PTB domain potentially
corresponding to residues 220–245 [16]. Indeed, puriﬁed con-
structs including this region can bind CCM3 [9]. To conﬁrm that
the newly identiﬁed C-terminal domain of CCM2 does not bind
CCM3, we conducted pull-down experiments using immobilized
CCM2-FL or CCM2-HHD with puriﬁed CCM3 as input. We ob-
served that while CCM2-FL pulls down CCM3, CCM2-HHD does
not (Fig. 1D).
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The proteolytically resistant C-terminal domain of CCM2 has
low primary sequence similarity to previously determined struc-
tures, suggesting that it may comprise a novel fold. We therefore
determined its structure by X-ray crystallography by using the
SAD method (Fig. S1), and reﬁned against a 1.9 Å native dataset
(Table S1). Overall, we found good electron density throughout
the structure (Fig. S1), with four copies of CCM2 per asymmetric
unit. The CCM2 C-terminus folds as a globular domain comprised
of a ﬁve-helical bundle that we denote as helices H1 to H5 with
a 4-residue helix (H1⁄) present at the N-terminus of chains A and
B. Although helices H1, H2, H3, H5, and H1⁄ are a-helices, helix
H4 is a long 13-residue 310 helix (Fig. 2A and B). A 310 helix of this
length is uncommon, as the majority of 310 helices observed in pro-
tein structures are typically only 3 or 4 residues [17]. Occasionally,
however, helices of comparable length are found, as discussed in a
2006 survey of 310 helices in the Protein Data Bank [17] that cited a
15 residue helix in PDB 1PZ4 [18]. The low frequency of longer 310
helices is likely due to decreased structural stability, resulting in
more stringent packing requirements [19]. The 310 helix of CCM2
packs against helices H1 and H5 and is anchored by two salt
bridges at its N- and C-termini made by residues R346 and R354
binding helix H1 residue E314 and helix H5 residue E366, respec-
tively. The conserved P355–F356 pair at the C-terminus of H4 is
also potentially important for stabilizing this helix (Fig. 2C). The
overall structure of CCM2-HHD encompasses residues S283–K375.
3.4. The CCM2 C-terminal domain is homologous to the N-terminal
domain of harmonin
To investigate whether the C-terminal domain of CCM2 folds
in a similar fashion to previously determined structures, weFig. 2. Overall structure of CCM2 harmonin-homology domain (HHD). (A) cartoon diag
using CCP4MG [20]; (B) topology diagram of the CCM2 HHD generated using TopDraw; (
regions that stabilize the 310 helix: a salt bridge between R354 and E346 (upper left), a
F356 (upper right); (D) superposition of the N-domain of harmonin (PDB ID: 3K1R) [14] i
the harmonin N-domain generated using Aline. The secondary structure of CCM2 is depic
a-helices are shown as cylinders and 310 helices as spirals. Residues highlighted in ye
residues that bind cadherin 23.submitted each of the four chains to the Dali server. We found that
there is distinct structural similarity to the Usher syndrome scaf-
folding protein harmonin (PDB IDs: 3K1R, 2KBQ, 2KBR) [14,15], a
protein involved in mechanotransduction in hair cell bundles
(Fig. 2D). Although sequence identity between the CCM2 C-termi-
nal domain and the harmonin N-terminal domain is only 14% over
80 residues (Fig. 2E), the Dali server yielded Z-scores between
CCM2 and harmonin that ranged from 8.6 to 11.9 and root-
mean-square deviations (RMSD) from 1.7 to 2.6 Å over 71–80 Ca
atoms. Based on this structural similarity, we therefore denote this
domain in CCM2 the harmonin-homology domain, or HHD.
3.5. The CCM2 HHD crystal structure indicates two conformational
states
The CCM2 HHD crystallizes with four copies per asymmetric
unit. Analysis of the crystal packing reveals two distinct conforma-
tions. Two of the copies (chains A and B) have an extensive inter-
action interface between them (Fig. 3A), but this interface is not
observed for the other two copies (chains C and D) either in the
asymmetric unit or with symmetry-related molecules. Chains A
and B are experimentally identical (RMSD is 0.55 Å over 93 Ca
[20]) and chains C and D are structurally very similar (RMSD is
0.75 Å over 76 Ca). The two classes (A/B and C/D), however, are
conformationally more divergent from one another (e.g., the RMSD
between chains A and D is 1.39 Å over 76 Ca). This divergence is
centered on the N-terminal portion of the CCM2 HHD up to residue
S311 (RMSD for residues 311–375 between chains A and D is
0.87 Å over 65 Ca) (Fig. 3B). Although there is strong electron den-
sity for residues S283–S311 in both chains A and B, this N-terminal
region is partly disordered in chains C and D, for which S292 and
L299 are the ﬁrst visible residues, respectively. Furthermore, in
the visible N-terminal portions of chains C and D, helix H1 isram of the CCM2 HHD (chain A) with helices labeled. Structural images generated
C) cartoon diagram of CCM2 with the 310 helix (H4) highlighted in teal. Insets show
salt bridge between R346 and E314 (lower right), and conserved residues P355 and
n orange and the CCM2 HHD in teal; (E) structure-based alignment of CCM2 HHD to
ted above its sequence and the secondary structure of harmonin below its sequence.
llow are conserved between CCM2 and harmonin. Red triangles denote harmonin
Fig. 3. The CCM2 harmonin-homology domain putative dimerization interface. (A) Crystallographically observed interaction interface between CCM2 HHD chains A and B.
Chain A is colored in teal and chain B in purple; (B) superposition of the four molecules in the ASU. Chain A is colored in teal, B in purple, C in yellow, and D in green. The hinge
residue S311 is indicated by an arrow. Inset shows the two conformations of helix H1. Schematic illustrates the conformational change in helix H1; (C) map of residues
involved in the CCM2 HHD interface. Residue E290 is mutated in this study and indicated in red; (D) chain B shown in surface view and A as a ribbon diagram. Residues
involved in mediating the interface are depicted in purple or teal for chain B or A respectively. Insets are close-ups of key residues involved in the hydrophobic pocket (left)
and charge cluster (right); (E) superposition of chain C (yellow) on chain A, with chain B shown as a surface. The two CCM2 HHD conformations are incompatible with each
other.
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HHD by approximately 20 (by HELIXANG) and pivots around res-
idue S311 (Fig. 3B).
3.6. Structural analysis of the interface between chains A and B
The crystallographically observed interface between chains A
and B encompasses 18 residues from each chain, and comprises
9 hydrogen bonds and 109 non-bonded contacts (as deﬁned by
PDBSum) (Fig. 3C). The interface between molecules A and B buries
a total surface area of 1911 Å2 (956.9 Å2 from chain A and 954.1 Å2
from chain B) as deﬁned by the PISA server and has a shape com-
plementarity of 0.64 [21] (Fig. 3D). The PISA server also shows this
interface to have a Complex Formation Signiﬁcance Score (CSS), a
measure of interface relevance, of 1.000. The interaction is almost
twofold symmetric and encompasses the N-terminus through res-
idue Q300 and residues Q316–N327. This includes helix H1⁄, the N-
terminal portion of helix H1, and the C-terminal portion of helix
H2. The interaction surface is predominantly comprised of three
regions: two hydrophobic pockets and a charge cluster. Because
of the almost twofold symmetry, the charge cluster is found at
the center of the interface and the hydrophobic pockets on the
edge (Fig. 3E) (Supplementary data).
3.7. Determination of the oligomeric state of the CCM2 HHD by size
exclusion chromatography with light scattering and analytical
ultracentrifugation
Because of the presence of both monomeric and dimeric forms
of the CCM2 HHD in the crystal structure and the fact that the di-
meric interface is evolutionarily conserved (Fig. S2), we tested the
oligomeric state of the CCM2 HHD by size exclusion chromatogra-
phy coupled with multi-angle light scattering (SEC-MALS). Wefound that both dimeric and monomeric forms of CCM2-HHD are
present in solution as determined by SEC-MALS, with the mono-
meric species making up the majority of the protein (Fig. 4A).
We also conﬁrmed that the dimeric peak was CCM2-HHD by N-ter-
minal sequencing and that dimerization was not due to disulﬁde
formation by analysis of non-reducing SDS–PAGE (data not
shown). We next generated a point mutation at the dimer inter-
face, E290R, and found by SEC-MALS that the small dimeric peak
was no longer observed (Fig. 4B).
Since our light scattering data neither completely rule out the
existence of a CCM2-HHD dimer nor fully validate it, we next
sought to study the dimerization equilibrium of the putative dimer
by analytical ultracentrifugation (AUC). Sedimentation velocity
experiments (SV) were carried out to determine the oligmeric state
of CCM2-HHD and CCM2-HHD-E290R. We examined both wild-
type and mutant over a range of loading concentrations to deter-
mine any possible mass action effects (Table S2). These experi-
ments showed homogeneous compositions for both wild-type
and mutant (Fig. 4C), resulting in molecular weights consistent
only with a monomer of CCM2-HHD (Fig. 4D). Sedimentation pro-
ﬁles from multiple loading concentrations did not produce any
change in the sedimentation behavior, suggesting the absence of
any mass action. Both wild-type and mutant displayed essentially
identical sedimentation coefﬁcients at all investigated concentra-
tions. While the sedimentation resulted in observations of mono-
meric protein, these experiments were carried out at
concentrations substantially lower than the crystallization experi-
ments. These results do not preclude a monomer–dimer afﬁnity in
the concentration range present during crystallizations. However,
AUC experiments conducted at such high concentrations may be
problematic.
Together, the SEC-MALS and AUC results suggest that the
homodimer observed in the crystal structure may represent a weak
Fig. 4. Size exclusion chromatography with multi-angle light scattering (SEC-MALS) and analytical ultracentrifugation (AUC) analysis of CCM2 HHD. (A) SEC-MALS analysis of
the 11.1 kDa CCM2-HHD. Two peaks are observed: a monomeric peak with a molecular weight of 11.1 kDa ±2% and a dimeric peak with a molecular weight of 19 kDa ±2%.
Molar mass is plotted on the primary y-axis, and normalized A280 on the secondary y-axis; (B) SEC-MALS analysis of CCM2-HHD-E290R. One peak is observed, with molecular
weight of 11.1 kDa ±1.4%; (C) van Holde–Weischet sedimentation coefﬁcient distributions for CCM2-HHD (left), measured at 0.59 OD230 (red), 1.14 OD230 (green), 0.4 OD280
(magenta), and 1.0 OD280 (blue), and CCM2-HHD-E290R (right), measured at 0.49 OD230 (red), 1.1 OD230 (green), 0.37 OD280 (magenta), and 1.07 OD280 (blue). The narrow
sedimentation distribution of both CCM2-HHD and CCM2-HHD-E290R forms indicates homogeneity, and suggests that all concentrations reﬂect the same oligomeric state;
(D) 2-dimensional spectrum analysis ﬁt combined with a 50 iteration Monte Carlo analysis. CCM2-HHD (left) and CCM2-HHD-E290R (right). The plots show a major species
with a molecular weight consistent with the monomer (10.9 kDa, 95% conﬁdence intervals: 9.3, 12.6 kDa). The y-axis denotes the anisotropy of the molecule, which suggests
a mostly globular structure with a value of 1.35 (95% conﬁdence interval: 1.25, 1.44). The color scale on the right y-axis denotes relative concentration.
Fig. 5. CCM2 HHD crystallographic dimerization interface is analogous to harmonin–cadherin 23 interface. (A) structure of harmonin N-terminal domain (orange) bound to a
cadherin 23 peptide in red (PDB ID: 2KBR) [15]; (B) superposition of CCM2-HHD (teal) and harmonin (orange). Cadherin 23 is shown (red). Exploded view shows speciﬁc
residues that clash between CCM2-HHD and cadherin 23 in the superposition; (C) superposition of the CCM2-HHD dimer onto harmonin. The cadherin binding site is
equivalent to the dimer interface between CCM2 HHD chain A (left, interface residues teal) and chain B (right, interface residues purple).
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These studies do not, however, preclude the potential that other
regions of CCM2 or CCM2 binding partners could facilitate forma-
tion of this dimerization interface.
3.8. The crystallographic CCM2 HHD dimerization interface resembles
the harmonin–cadherin 23 binding site
The CCM2 HHD is structurally similar to the N-terminal domain
of the Usher syndrome protein harmonin (Fig. 2D). Harmonin binds
directly to the cell adhesion protein cadherin 23 via two domains:
its N-terminal domain and a PDZ domain. The structural basis for
the harmonin N-terminal domain binding to cadherin 23 has been
determined by NMR spectroscopy [15] (Fig. 5A), so we compared
this mode of binding to the crystallographically-observed CCM2
HHD dimer. We found that the CCM2 HHD dimer interface occu-
pies a similar location to that observed for the harmonin interac-
tion with cadherin 23 (Fig. 5B and C). Although we did not
observe direct interaction between CCM2-HHD and cadherin 23
(data not shown) we suggest that the equivalent surface in CCM2
HHD could potentially mediate other protein–protein interactions.
4. Discussion
Understanding the function and role of proteins associated with
cerebral cavernous malformations has recently become an area of
intense interest, as KRIT1, CCM2, and CCM3 have been found to
be involved in diverse signaling pathways. These include regula-
tion of integrin activation, degradation of Rho-family GTPases
and receptor tyrosine kinases, stabilization of VEGFR2, interactions
with MAP and sterile-20 kinases, and TrkA signaling. The discovery
of new regions within these proteins that can provide a functional
basis for understanding their signaling pathways could therefore
allow for signiﬁcant further studies. Previously, we discovered that
CCM3 contains an N-terminal dimerization domain of a novel fold,
and a C-terminal focal adhesion targeting (FAT)-homology domain
[9], allowing us to discover interesting new functions and roles for
CCM3 [22,23]. Likewise, the current study provides the ﬁrst molec-
ular level description of CCM2: the discovery of a previously
uncharacterized folded domain at its C-terminus that we term
the CCM2 harmonin homology domain (HHD). Interestingly we ob-
serve two conformations for the CCM2 HHD in our structure.
The similarities between the CCM2 HHD dimerization interface
and the harmonin–cadherin 23 interface are interesting. The non-
overlapping interactions of the harmonin N-terminal and PDZ do-
mains with cadherin 23 are both of moderate afﬁnity (KD of
approximately 10–20 lM). Together, however, these facilitate a
tight harmonin–cadherin 23 complex [15]. Similarly, CCM2 could
also potentially utilize bidentate moderate afﬁnity interactions to
speciﬁc partners, perhaps via both the PTB and HHD domains.
Therefore, the discovery of the HHD provides an exciting new
level of understanding to these important proteins and will likely
spur new functional analyses of CCM2, its binding partners, and
their function.
Acknowledgements
We thank V. Schirf, W. Min, B. Turk, H.J. Lou, K. Draheim, A. Stie-
gler, W. Liu, N. Alicea-Velázquez, B.H. Ha, J. Chacon, D. Calderwood,
J. Ferrullo, and beamlines X25, X29, and NECAT. Grants from NSF
(O.S.F.), AHA (X.L.), NIH CA054174, RR022200 (B.D.), and NSF TG-
MCB070038 (B.D.). T.J.B. funded by the NIH.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2012.
12.011.
References
[1] Cavalcanti, D.D., Kalani, M.Y., Martirosyan, N.L., Eales, J., Spetzler, R.F. and
Preul, M.C. (2012) Cerebral cavernous malformations: from genes to proteins
to disease. J. Neurosurg. 116, 122–132.
[2] Akers, A.L., Johnson, E., Steinberg, G.K., Zabramski, J.M. and Marchuk, D.A.
(2009) Biallelic somatic and germline mutations in cerebral cavernous
malformations (CCMs): evidence for a two-hit mechanism of CCM
pathogenesis. Hum. Mol. Genet. 18, 919–930.
[3] Pagenstecher, A., Stahl, S., Sure, U. and Felbor, U. (2009) A two-hit mechanism
causes cerebral cavernous malformations: complete inactivation of CCM1,
CCM2 or CCM3 in affected endothelial cells. Hum. Mol. Genet. 18, 911–918.
[4] Boulday, G., Blecon, A., Petit, N., Chareyre, F., Garcia, L.A., Niwa-Kawakita, M.,
Giovannini, M. and Tournier-Lasserve, E. (2009) Tissue-speciﬁc conditional
CCM2 knockout mice establish the essential role of endothelial CCM2 in
angiogenesis: implications for human cerebral cavernous malformations. Dis.
Model. Mech. 2, 168–177.
[5] Whitehead, K.J. et al. (2009) The cerebral cavernous malformation signaling
pathway promotes vascular integrity via Rho GTPases. Nat. Med. 15, 177–184.
[6] Liquori, C.L. et al. (2003) Mutations in a gene encoding a novel protein
containing a phosphotyrosine-binding domain cause type 2 cerebral
cavernous malformations. Am. J. Hum. Genet. 73, 1459–1464.
[7] Stahl, S. et al. (2008) Novel CCM1, CCM2, and CCM3 mutations in patients with
cerebral cavernous malformations: in-frame deletion in CCM2 prevents
formation of a CCM1/CCM2/CCM3 protein complex. Hum. Mutat. 29, 709–717.
[8] Zawistowski, J.S., Stalheim, L., Uhlik, M.T., Abell, A.N., Ancrile, B.B., Johnson,
G.L. and Marchuk, D.A. (2005) CCM1 and CCM2 protein interactions in cell
signaling: implications for cerebral cavernous malformations pathogenesis.
Hum. Mol. Genet. 14, 2521–2531.
[9] Li, X., Zhang, R., Zhang, H., He, Y., Ji, W., Min, W. and Boggon, T.J. (2010) Crystal
structure of CCM3, a cerebral cavernous malformation protein critical for
vascular integrity. J. Biol. Chem. 285, 24099–24107.
[10] Zhou, X., Izumi, Y., Burg, M.B. and Ferraris, J.D. (2011) Rac1/osmosensing
scaffold for MEKK3 contributes via phospholipase C-gamma1 to activation of
the osmoprotective transcription factor NFAT5. Proc. Natl. Acad. Sci. USA 108,
12155–12160.
[11] Uhlik, M.T. et al. (2003) Rac-MEKK3-MKK3 scaffolding for p38 MAPK
activation during hyperosmotic shock. Nat. Cell. Biol. 5, 1104–1110.
[12] Crose, L.E., Hilder, T.L., Sciaky, N. and Johnson, G.L. (2009) Cerebral cavernous
malformation 2 protein promotes smad ubiquitin regulatory factor 1-
mediated RhoA degradation in endothelial cells. J. Biol. Chem. 284, 13301–
13305.
[13] Harel, L. et al. (2009) CCM2 mediates death signaling by the TrkA receptor
tyrosine kinase. Neuron 63, 585–591.
[14] Yan, J., Pan, L., Chen, X., Wu, L. and Zhang, M. (2010) The structure of the
harmonin/sans complex reveals an unexpected interaction mode of the two
Usher syndrome proteins. Proc. Natl. Acad. Sci. USA 107, 4040–4045.
[15] Pan, L., Yan, J., Wu, L. and Zhang, M. (2009) Assembling stable hair cell tip link
complex via multidentate interactions between harmonin and cadherin 23.
Proc. Natl. Acad. Sci. USA 106, 5575–5580.
[16] Kean, M.J. et al. (2011) Structure–function analysis of core STRIPAK proteins: a
signaling complex implicated in golgi polarization. J. Biol. Chem. 286, 25065–
25075.
[17] Enkhbayar, P., Hikichi, K., Osaki, M., Kretsinger, R.H. and Matsushima, N.
(2006) 3(10)-Helices in proteins are parahelices. Proteins 64, 691–699.
[18] Dyer, D.H., Lovell, S., Thoden, J.B., Holden, H.M., Rayment, I. and Lan, Q. (2003)
The structural determination of an insect sterol carrier protein-2 with a
ligand-bound C16 fatty acid at 1.35-A resolution. J. Biol. Chem. 278, 39085–
39091.
[19] Vieira-Pires, R.S. and Morais-Cabral, J.H. (2010) 3(10) Helices in channels and
other membrane proteins. J. Gen. Physiol. 136, 585–592.
[20] McNicholas, S., Potterton, E., Wilson, K.S. and Noble, M.E. (2011) Presenting
your structures: the CCP4mgmolecular-graphics software. Acta Crystallogr. D:
Biol. Crystallogr. 67, 386–394.
[21] Lawrence, M.C. and Colman, P.M. (1993) Shape complementarity at protein/
protein interfaces. J. Mol. Biol. 234, 946–950.
[22] Li, X., Ji, W., Zhang, R., Folta-Stogniew, E., Min, W. and Boggon, T.J. (2011)
Molecular recognition of LD motifs by the FAT-homology domain of cerebral
cavernous malformation 3 (CCM3). J. Biol. Chem. 286, 26138–26147.
[23] He, Y., Zhang, H., Yu, L., Gunel, M., Boggon, T.J., Chen, H. and Min, W. (2010)
Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is
critical for vascular development. Sci. Signal. 3, ra26.
